ACAD News and Press, ACADIA Pharmaceuticals Inc.

-- Experienced global HR leader joins Acadia to advance people strategy and support the next phase of growth Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company’s glo...

2026-07-01 13:08:40 ET The equity markets wrapped up a very profitable second quarter and first half of 2026 on Tuesday. Despite the conflict in Iran, the NASDAQ rose 20% in Q2, and the S&P 500 was up 14%. And this was with the Magnificent Seven losing approximately $2.3 trillio...

2026-06-30 09:38:16 ET The last time I spoke about Taysha Gene Therapies ( TSHA ) it was with a Seeking Alpha article entitled " Taysha: TSHA-102 Presses On With IND Part B Protocol And SAP Amendments ." With respect to this article, I mentioned that it had reported additional p...

2026-06-29 11:19:58 ET It has been more than a year since I last wrote about Acadia Pharmaceuticals ( ACAD ). Since then, we saw the failure of ACP-101 in Prader-Willi syndrome, which I wrote was a realistic possibility last year due to the issues I saw with prior clinical d...

2026-06-29 10:15:13 ET David Hoang from Deutsche Bank issued a price target of $37.00 for ACAD on 2026-06-29 12:52:16. The adjusted price target was set to $37.00. At the time of the announcement, ACAD was trading at $25.0567. The overall price target consensus is at $34...

2026-06-26 12:37:59 ET Already recovering from weakness suffered early this year, Acadia Pharmaceuticals (NASDAQ: ACAD) shares were outright catapulted higher today. Indeed, the pharmaceutical stock's 12.2% gain as of 12:17 p.m. ET Friday has pushed it back within sight of its 52-we...

2026-06-26 11:22:45 ET More on Acadia Pharma Acadia Pharmaceuticals: The Song Remains The Same ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcr...

-- European Commission decision expected in the coming months -- If approved, DAYBU ® would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee...

2026-06-22 09:11:05 ET It has been just over a year since my last look at ACADIA Pharmaceuticals Inc. ( ACAD ) in May 2025. I concluded that article by stating ACAD remains a solid covered call holding. The stock has moved up roughly 20% since that conclusion. Has the pr...

2026-05-14 14:40:38 ET More on Acadia Pharmaceuticals ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript ACADIA Pharmaceuticals Inc. 2026 Q1 -...